New combination therapy found to be well tolerated in patients with aggressive brain tumor

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumor has found the treatment to be well tolerated in patients.

The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.

In the trial, led by Professor Peter Szloserek from Queen Mary University of London and Barts Health NHS Trust, ten patients with heavily pre-treated, recurrent HGG were treated with ADI-PEG20 in combination with standard chemotherapies pemetrexed and cisplatin.

Read more on this story at: https://www.news-medical.net/news/20190330/New-combination-therapy-found-to-be-well-tolerated-in-patients-with-aggressive-brain-tumor.aspx

Posted in News

Become a member

Benefits of membership include:

  • Phone and peer support for sufferers and carers
  • Regular updates on issues relating to asbestos exposure and disease
  • Occupational therapy assessment and, if needed, follow-up through our contracted occupational therapist
Join today